BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 962 filers reported holding BAXTER INTL INC in Q3 2014. The put-call ratio across all filers is 1.07 and the average weighting 0.4%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2023 | $226 | -100.0% | 4,959 | -92.6% | 0.05% | -95.9% |
Q1 2022 | $5,197,000 | +278.8% | 67,021 | +319.2% | 1.13% | +260.0% |
Q4 2021 | $1,372,000 | -13.1% | 15,986 | -18.5% | 0.32% | -31.8% |
Q2 2021 | $1,578,000 | +147.3% | 19,606 | +164.7% | 0.46% | +96.6% |
Q2 2020 | $638,000 | -96.9% | 7,407 | -97.2% | 0.24% | -68.5% |
Q3 2018 | $20,423,000 | +15.9% | 264,920 | -2.3% | 0.75% | +11.8% |
Q1 2018 | $17,627,000 | -11.0% | 271,025 | -14.1% | 0.67% | -9.4% |
Q3 2017 | $19,799,000 | +81.8% | 315,528 | +75.4% | 0.74% | +80.2% |
Q2 2017 | $10,889,000 | +517.6% | 179,863 | +429.2% | 0.41% | +510.4% |
Q1 2017 | $1,763,000 | -93.1% | 33,989 | -94.1% | 0.07% | -93.5% |
Q4 2016 | $25,430,000 | +105.5% | 573,515 | +120.6% | 1.04% | +101.2% |
Q3 2016 | $12,373,000 | +30.2% | 259,937 | +23.7% | 0.52% | +35.9% |
Q2 2016 | $9,500,000 | +288.9% | 210,079 | +182.5% | 0.38% | +238.4% |
Q3 2015 | $2,443,000 | -62.6% | 74,355 | -22.0% | 0.11% | -51.9% |
Q1 2015 | $6,533,000 | -81.6% | 95,366 | -80.6% | 0.23% | -75.6% |
Q2 2014 | $35,566,000 | +43.7% | 491,924 | +30.6% | 0.95% | +30.7% |
Q3 2013 | $24,750,000 | +131.4% | 376,774 | +144.0% | 0.73% | +104.5% |
Q2 2013 | $10,695,000 | – | 154,402 | – | 0.36% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
JONES ROAD CAPITAL MANAGEMENT, L.P. | 200,000 | $7,548,000 | 6.60% |
BOONE CAPITAL MANAGEMENT LLC | 469,405 | $17,715,345 | 5.59% |
Soditic Asset Management LLP | 186,920 | $7,054,361 | 5.43% |
JONES ROAD CAPITAL MANAGEMENT, L.P. | 131,000 | $4,943,940 | 4.32% |
Camber Capital Management LP | 3,000,000 | $113,220 | 3.73% |
Carmignac Gestion | 4,848,773 | $182,991,718 | 3.36% |
SHAPIRO CAPITAL MANAGEMENT LLC | 3,028,799 | $114,306,874 | 3.33% |
Hillman Capital Management, Inc. | 219,248 | $8,274,420 | 3.19% |
Cincinnati Specialty Underwriters Insurance CO | 201,500 | $7,604,610 | 2.90% |
Callodine Capital Management, LP | 265,000 | $10,001,100 | 2.79% |